Department of Hematology and Oncology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany.
Haematologica. 2010 May;95(5):810-8. doi: 10.3324/haematol.2009.011809. Epub 2009 Dec 8.
Disease stage is the most important prognostic parameter in allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia, but other factors such as donor/host histocompatibility and gender combination, recipient age, performance status and comorbidities need to be considered. Several scoring systems are available to predict outcome in HCT recipients; however, their prognostic relevance in acute lymphoblastic leukemia is not well defined.
In the present study we evaluated a modified EBMT risk score (mEBMT) and the HCT-specific comorbidity index (HCT-CI) in 151 adult acute lymphoblastic leukemia patients who received allogeneic HCT from 1995 until 2007 at our center.
Disease status was first complete remission (CR1) (47%), CR>1 (21%) or no CR (32%). Overall survival (OS) at one, two and five years was 62%, 51% and 40% and non-relapse mortality (NRM) was 21%, 24% and 32%. Median mEBMT was 3 (0-6). Higher mEBMT was associated with inferior OS (hazard ratio per score unit (HR): 1.50, P<0.001), higher NRM (HR: 1.36, P=0.042) and higher relapse mortality (HR: 1.68, P<0.001). Disease stage was the predominant prognostic factor in this score. Comorbidities were present in 71% of patients with mild hepatic disease (29%), moderate pulmonary disease (28%) and infections (23%) being the most common. Median HCT-CI was 1 (0-9). In univariate analysis a trend for inferior OS (HR: 1.08, P=0.20) and higher NRM (HR: 1.14, P=0.11) with increasing HCT-CI was observed but the level of significance was not reached. In additional analyses we found that reduced Karnofsky Performance Status (KPS) was associated with inferior OS (HR: 1.34, P=0.023) and higher relapse mortality (HR: 1.71, P=0.001) when analyzed univariately. However, KPS was associated with disease stage and significance was lost in multivariate analysis.
The mEBMT was prognostic in our patient cohort with predominant influence of disease stage, whereas a trend but no significant prognostic value was observed for the HCT-CI.
疾病分期是异基因造血细胞移植(HCT)治疗急性淋巴细胞白血病(ALL)最重要的预后参数,但还需要考虑其他因素,如供体/宿主组织相容性和性别组合、受者年龄、表现状态和合并症。有几种评分系统可用于预测 HCT 受者的预后;然而,它们在急性淋巴细胞白血病中的预后相关性尚不清楚。
本研究中,我们评估了改良的 EBMT 风险评分(mEBMT)和 HCT 特异性合并症指数(HCT-CI)在 151 例成人急性淋巴细胞白血病患者中的应用,这些患者于 1995 年至 2007 年在我们中心接受了异基因 HCT。
疾病状态为首次完全缓解(CR1)(47%)、CR>1(21%)或无 CR(32%)。1、2、5 年总生存率(OS)分别为 62%、51%和 40%,非复发死亡率(NRM)分别为 21%、24%和 32%。mEBMT 中位数为 3(0-6)。较高的 mEBMT 与较差的 OS 相关(每增加一个评分单位的风险比(HR):1.50,P<0.001)、较高的 NRM(HR:1.36,P=0.042)和较高的复发死亡率(HR:1.68,P<0.001)。疾病分期是该评分中的主要预后因素。71%的患者存在合并症,其中轻度肝疾病(29%)、中度肺疾病(28%)和感染(23%)最常见。HCT-CI 的中位数为 1(0-9)。在单因素分析中,OS(HR:1.08,P=0.20)和 NRM(HR:1.14,P=0.11)呈下降趋势,但未达到显著水平。在进一步的分析中,我们发现当单独分析时,较低的 Karnofsky 表现状态(KPS)与较差的 OS(HR:1.34,P=0.023)和较高的复发死亡率(HR:1.71,P=0.001)相关。然而,KPS 与疾病分期相关,且在多因素分析中失去了意义。
mEBMT 在我们的患者队列中具有预后意义,主要受疾病分期的影响,而 HCT-CI 则呈现出趋势,但无显著的预后价值。